Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
09
02
2022
accepted:
08
07
2022
revised:
06
07
2022
pubmed:
24
7
2022
medline:
7
10
2022
entrez:
23
7
2022
Statut:
ppublish
Résumé
The development of non-relapse cytopenias (NRC) is a relatively common occurrence post allogeneic stem cell transplant (alloSCT). Whilst there have been attempts to classify post alloSCT cytopenias by transplantation groups, ambiguity of definitions in prior publications compounded by a lack of availability of high-quality evidence, provide challenges to clinicians attempting to manage these complex patients. In this review we describe 3 cases of NRC, (1) Graft Failure with graft rejection representing cytopenias with minimal donor chimerism (2) Poor Graft Function representing cytopenias with complete donor chimerism and (3) Cytopenias with mixed donor chimerism. This case-based review will evaluate the currently available evidence regarding the pathophysiology of each entity as well as the evidence for current therapies with the aim of providing guidance to clinicians managing these complex patients.
Identifiants
pubmed: 35871087
doi: 10.1038/s41409-022-01761-z
pii: 10.1038/s41409-022-01761-z
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1489-1499Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Valcárcel D, Sureda A. Graft failure. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Cham (CH): Springer Copyright 2019, EBMT and the Author(s). 2019. p. 307-13.
Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the american society for transplantation and cellular therapy. Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther. 2021;27:642–9.
Olsson RF, Logan BR, Chaudhury S, Zhu X, Akpek G, Bolwell BJ, et al. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia. 2015;29:1754–62.
pubmed: 25772027
pmcid: 4527886
doi: 10.1038/leu.2015.75
Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505:327–34.
pubmed: 24429631
pmcid: 4514480
doi: 10.1038/nature12984
Kokkaliaris KD, Scadden DT. Cell interactions in the bone marrow microenvironment affecting myeloid malignancies. Blood Adv. 2020;4:3795–803.
pubmed: 32780848
pmcid: 7422101
doi: 10.1182/bloodadvances.2020002127
Fisher DAC, Fowles JS, Zhou A, Oh ST. Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms. Front Immunol. 2021;12. https://doi.org/10.3389/fimmu.2021.683401 .
Xingmin F, Phillip S, Colin OW, Leigh S, Olga N, Courtney P, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica. 2011;96:602–6.
doi: 10.3324/haematol.2010.030536
Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transpl. 2013;48:537–43.
doi: 10.1038/bmt.2012.239
Park JH, Lee JH, Lee JH, Park HS, Choi EJ, Kang YA, et al. Incidence, management, and prognosis of graft failure and autologous reconstitution after allogeneic hematopoietic stem cell transplantation. J Korean Med Sci. 2021;36:e151.
pubmed: 34128593
pmcid: 8203852
doi: 10.3346/jkms.2021.36.e151
Kernan NA, Flomenberg N, Dupont B, O’Reilly RJ. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation. 1987;43:842–7.
pubmed: 3296349
doi: 10.1097/00007890-198743060-00014
Nakamura H, Gress RE. Graft rejection by cytolytic T cells. Specificity of the effector mechanism in the rejection of allogeneic marrow. Transplantation. 1990;49:453–8.
pubmed: 2305471
doi: 10.1097/00007890-199002000-00042
Voogt PJ, Fibbe WE, Marijt WA, Goulmy E, Veenhof WF, Hamilton M, et al. Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet. 1990;335:131–4.
pubmed: 1967432
doi: 10.1016/0140-6736(90)90003-N
Masouridi-Levrat S, Simonetta F, Chalandon Y. Immunological basis of bone marrow failure after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7. https://doi.org/10.3389/fimmu.2016.00362 .
Jiang Z, Adams GB, Hanash AM, Scadden DT, Levy RB. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation. Biol Blood Marrow Transpl. 2002;8:588–96.
doi: 10.1053/bbmt.2002.v8.abbmt080588
Hanash AM, Levy RB. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood. 2005;105:1828–36.
pubmed: 15494429
doi: 10.1182/blood-2004-08-3213
Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88:1019–24.
pubmed: 19855248
pmcid: 4324621
doi: 10.1097/TP.0b013e3181b9d710
Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011;118:5957–64.
pubmed: 21967975
pmcid: 3761379
doi: 10.1182/blood-2011-06-362111
Cutler C, Kim HT, Sun L, Sese D, Glotzbecker B, Armand P, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011;118:6691–7.
pubmed: 21940825
pmcid: 3976219
doi: 10.1182/blood-2011-05-355263
Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transpl. 2012;47:508–15.
doi: 10.1038/bmt.2011.131
Xie Y, Parekh J, Tang Z, Wu D, Wu X. Donor-specific antibodies and primary graft failure in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Transpl Cell Ther. 2021;27:687.e1–7.
doi: 10.1016/j.jtct.2021.04.030
Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, et al. Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2015;21:1392–8.
doi: 10.1016/j.bbmt.2015.05.001
Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol. 2000;111:292–302.
pubmed: 11091216
Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, Papadopoulos EB, Small TN, et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transpl. 2007;13:1313–23.
doi: 10.1016/j.bbmt.2007.07.006
Lund TC, Liegel J, Bejanyan N, Orchard PJ, Cao Q, Tolar J, et al. Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure. Am J Hematol. 2015;90:892–6.
pubmed: 26149534
pmcid: 4579006
doi: 10.1002/ajh.24111
Harada K, Fuji S, Seo S, Kanda J, Ueki T, Kimura F, et al. Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2020;55:1784–95.
pubmed: 32051535
doi: 10.1038/s41409-020-0821-9
Kongtim P, Bittencourt M, Srour SA, Ramdial J, Rondon G, Chen J, et al. Haploidentical transplants for patients with graft failure after the first allograft. Am J Hematol. 2020;95:E267–9.
Prata PH, Resche-Rigon M, Blaise D, Socié G, Rohrlich P-S, Milpied N, et al. Outcomes of salvage haploidentical transplant with post-transplant cyclophosphamide for rescuing graft failure patients: a report on behalf of the francophone society of bone marrow transplantation and cellular therapy. Biol Blood Marrow Transplant. 2019;25:1798–802.
pubmed: 31129355
doi: 10.1016/j.bbmt.2019.05.013
Giammarco S, Raiola AM, Di Grazia C, Bregante S, Gualandi F, Varaldo R, et al. Second haploidentical stem cell transplantation for primary graft failure. Bone Marrow Transplant. 2021;56:1291–6.
pubmed: 33328569
doi: 10.1038/s41409-020-01183-9
Park JA, Koh KN, Choi ES, Jang S, Kwon SW, Park CJ, et al. Successful rescue of early graft failure in pediatric patients using T-cell-depleted haploidentical hematopoietic SCT. Bone Marrow Transplant. 2014;49:270–5.
pubmed: 24141651
doi: 10.1038/bmt.2013.163
Tang BL, Zhu XY, Zheng CC, Liu HL, Geng LQ, Wang XB, et al. Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients. Bone Marrow Transpl. 2015;50:248–52.
doi: 10.1038/bmt.2014.250
Sun Y-Q, Wang Y, Wang F-R, Yan C-H, Cheng Y-F, Chen Y-H, et al. Graft failure in patients with hematological malignancies: a successful salvage with a second transplantation from a different haploidentical donor. Front Med. 2021;8. https://doi.org/10.3389/fmed.2021.604085 .
Yoshihara S, Ikegame K, Taniguchi K, Kaida K, Kim EH, Nakata J, et al. Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning. Bone Marrow Transpl. 2012;47:369–73.
doi: 10.1038/bmt.2011.84
Harada K, Kimura SI, Fuji S, Najima Y, Yakushijin K, Uchida N, et al. Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2021;56:2183–93.
doi: 10.1038/s41409-021-01310-0
Prabahran AA, Koldej R, Chee L, Ritchie DS. Clinical features, pathophysiology and therapy of poor graft function post allogeneic stem cell transplantation. Blood Advances. 2022;6:1947–59.
Bonifazi F, Barbato F, Ravaioli F, Sessa M, Defrancesco I, Arpinati M, et al. Diagnosis and treatment of VOD/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:489.
pubmed: 32318059
pmcid: 7147118
doi: 10.3389/fimmu.2020.00489
Shi MM, Kong Y, Song Y, Sun YQ, Wang Y, Zhang XH, et al. Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood. 2016;128:2988–99.
pubmed: 27769957
doi: 10.1182/blood-2016-03-702803
Alchalby H, Yunus DR, Zabelina T, Ayuk F, Kroger N. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transpl. 2016;51:1223–7.
doi: 10.1038/bmt.2016.98
Prabahran A, Koldej R, Chee L, Wong E, Ritchie D. Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation. Leuk Lymphoma. 2021;62:1482–9.
pubmed: 33522344
doi: 10.1080/10428194.2021.1872072
Alvarado LJ, Huntsman HD, Cheng H, Townsley DM, Winkler T, Feng X, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ. Blood. 2019;133:2043–55.
pubmed: 30803992
pmcid: 6509545
doi: 10.1182/blood-2018-11-884486
Shono Y, Ueha S, Wang Y, Abe J, Kurachi M, Matsuno Y, et al. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood. 2010;115:5401–11.
pubmed: 20354171
doi: 10.1182/blood-2009-11-253559
Zhao H-Y, Lyu Z-S, Duan C-W, Song Y, Han T-T, Mo X-D, et al. An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2018;182:679–92.
pubmed: 29974948
doi: 10.1111/bjh.15452
Kong Y, Wang Y-T, Cao X-N, Song Y, Chen Y-H, Sun Y-Q, et al. Aberrant T cell responses in the bone marrow microenvironment of patients with poor graft function after allogeneic hematopoietic stem cell transplantation. J Transl Med. 2017;15:57.
pubmed: 28292332
pmcid: 5351211
doi: 10.1186/s12967-017-1159-y
Mahat U, Rotz SJ, Hanna R. Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2020;26:e65–73.
doi: 10.1016/j.bbmt.2019.12.003
Larocca A, Piaggio G, Podesta M, Pitto A, Bruno B, Di Grazia C, et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica. 2006;91:935–40.
pubmed: 16818281
Ghobadi A, Fiala MA, Ramsingh G, Gao F, Abboud CN, Stockerl-Goldstein K, et al. Fresh or cryopreserved CD34(+)-selected mobilized peripheral blood stem and progenitor cells for the treatment of poor graft function after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2017;23:1072–7.
doi: 10.1016/j.bbmt.2017.03.019
Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, et al. CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. Biol Blood Marrow Transpl. 2014;20:382–6.
doi: 10.1016/j.bbmt.2013.11.034
Mainardi C, Ebinger M, Enkel S, Feuchtinger T, Teltschik HM, Eyrich M, et al. CD34(+) selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. Br J Haematol. 2018;180:90–9.
pubmed: 29205259
doi: 10.1111/bjh.15012
Mohty R, Brissot E, Battipaglia G, Ruggeri A, Sestili S, Mediavilla C, et al. CD34(+)-selected stem cell “Boost” for poor graft function after allogeneic hematopoietic stem cell transplantation. Curr Res Transl Med. 2019;67:112–4.
Stasia A, Ghiso A, Galaverna F, Raiola AM, Gualandi F, Luchetti S, et al. CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2014;20:1440–3.
doi: 10.1016/j.bbmt.2014.05.016
Jiang S, Penack O, Terzer T, Schult D, Majer-Lauterbach J, Radujkovic A, et al. Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel. Haematologica. 2021;106:446–53.
pubmed: 31974195
doi: 10.3324/haematol.2019.238790
Kong Y, Chang YJ, Wang YZ, Chen YH, Han W, Wang Y, et al. Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:1465–73.
doi: 10.1016/j.bbmt.2013.07.014
Kong Y, Song Y, Hu Y, Shi MM, Wang YT, Wang Y, et al. Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants. Oncotarget. 2016;7:30892–906.
pubmed: 27105530
pmcid: 5058726
doi: 10.18632/oncotarget.8810
Kong Y, Wang Y, Zhang Y-Y, Shi M-M, Mo X-D, Sun Y-Q, et al. Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Adv. 2019;3:1303–17.
pubmed: 31015207
pmcid: 6482364
doi: 10.1182/bloodadvances.2018029454
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N. Engl J Med. 2017;377:2433–44.
pubmed: 29211658
doi: 10.1056/NEJMoa1706640
Blyth E, Clancy L, Simms R, Ma CK, Burgess J, Deo S, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013;121:3745–58.
pubmed: 23435462
doi: 10.1182/blood-2012-08-448977
John TD, Friend B, Yassine K, Sasa G, Bhar S, Salem B, et al. Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children’s Hospital experience. Bone Marrow Transpl. 2021;56:2797–803.
doi: 10.1038/s41409-021-01415-6
Burney C, Wadhera K, Breslin P, Pearce R, Wells M, Alajangi R, et al. BEAM-campath allogeneic stem cell transplant for patients with relapsed/refractory lymphoma: high incidence of long-term mixed donor-recipient chimerism and the response to donor lymphocyte infusions. Biol Blood Marrow Transpl. 2020;26:2271–8.
doi: 10.1016/j.bbmt.2020.08.028
Xu ZL, Cheng YF, Zhang YY, Mo XD, Han TT, Wang FR, et al. The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clin Transpl. 2021;35:e14160.
doi: 10.1111/ctr.14160
Chen H, Li XY, Zhan LP, Fang JP, Huang K, Li Y, et al. Prediction, management, and prognosis of mixed chimerism after hematopoietic stem cell transplantation in transfusion-dependent pediatric thalassemia patients. Pediatr Transpl. 2020;24:e13876.
doi: 10.1111/petr.13876
Faraci M, Bagnasco F, Leoni M, Giardino S, Terranova P, Subissi L, et al. Evaluation of chimerism dynamics after allogeneic hematopoietic stem cell transplantation in children with nonmalignant diseases. Biol Blood Marrow Transpl. 2018;24:1088–93.
doi: 10.1016/j.bbmt.2017.12.801
Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, et al. Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen. Biol Blood Marrow Transpl. 2015;21:1460–70.
doi: 10.1016/j.bbmt.2015.04.009
Kinsella FAM, Zuo J, Inman CF, Pearce H, Maggs L, Eldershaw SE, et al. Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cells. Blood Adv. 2019;3:734–43.
pubmed: 30824417
pmcid: 6418492
doi: 10.1182/bloodadvances.2018025502
Lejman M, Zawitkowska J, Zaucha-Prażmo A, Cienkusz M, Mroczkowska A, Kowalczyk J, et al. Influence of mixed chimerism on outcome in children with anaemia after haematopoietic stem cell transplantation. Vivo. 2019;33:2051–7.
doi: 10.21873/invivo.11703
Stikvoort A, Sundin M, Uzunel M, Gertow J, Sundberg B, Schaffer M, et al. Long-term stable mixed chimerism after hematopoietic stem cell transplantation in patients with non-malignant disease, shall we be tolerant? PLoS One. 2016;11:e0154737.
pubmed: 27152621
pmcid: 4859543
doi: 10.1371/journal.pone.0154737
Bernaudin F, Dalle JH, Bories D, de Latour RP, Robin M, Bertrand Y, et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica. 2020;105:91–101.
pubmed: 31097628
pmcid: 6939536
doi: 10.3324/haematol.2018.213207
Bhat DK, Olkhanud PB, Gangaplara A, Seifuddin F, Pirooznia M, Biancotto A, et al. Early myeloid derived suppressor cells (eMDSCs) are associated with high donor myeloid chimerism following haploidentical HSCT for sickle cell disease. Front Immunol. 2021;12. https://doi.org/10.3389/fimmu.2021.757279 .
Shaw A, Passweg JR, De La Fuente J, Bajwa R, Stein J, Al-Zaben A, et al. Relapse of aplastic anemia with majority donor chimerism (Donor-Type Aplasia) occurring late after bone marrow transplantation. Biol Blood Marrow Transpl. 2020;26:480–5.
doi: 10.1016/j.bbmt.2019.11.010
Breuer S, Preuner S, Fritsch G, Daxberger H, Koenig M, Poetschger U, et al. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia. 2012;26:509–19.
pubmed: 21926962
doi: 10.1038/leu.2011.244
Zhang Y, Li Y, Wu L, Zhou M, Wang C, Mo W, et al. Mixed chimerism after allogeneic hematopoietic stem cell transplantation for severe aplastic anemia. Hematology. 2021;26:435–43.
pubmed: 34130602
doi: 10.1080/16078454.2021.1938422
M. Cuadrado M, Richard MS, Mike W, Nishil P, Hanna R, Jude D, et al. Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. Haematologica. 2019;105:2639–46.
doi: 10.3324/haematol.2019.226340
Ren RR, Ma LM, Xie YX, Tian WW, Wang T. Effect of donor lymphocyte infusion from two types of donors on mixed chimerism with secondary graft failure after allogeneic hematopoietic stem cell transplantation. Transpl Cell Ther. 2022;28:152.e1–7.
doi: 10.1016/j.jtct.2021.12.017
Au WY, Chan EC, Lie AK, Liang R, Leung AY, Ma SK, et al. Poor engraftment after allogeneic bone marrow transplantation: role of chimerism analysis in treatment and outcome. Ann Hematol. 2003;82:410–5.
pubmed: 12750845
doi: 10.1007/s00277-003-0676-3
Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, et al. Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transpl. 2008;14:859–66.
doi: 10.1016/j.bbmt.2008.05.005
Passweg JR, Zhang MJ, Rocha V, Kan F, Champlin RE, Isola LM, et al. Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies. Biol Blood Marrow Transpl. 2011;17:1869–73.
doi: 10.1016/j.bbmt.2011.07.008
Ferra C, Sanz J, Diaz-Perez MA, Morgades M, Gayoso J, Cabrera JR, et al. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leuk Lymphoma. 2015;56:656–62.
pubmed: 24913510
doi: 10.3109/10428194.2014.930849
Cluzeau T, Lambert J, Raus N, Dessaux K, Absi L, Delbos F, et al. Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI. Bone Marrow Transpl. 2016;51:687–91.
doi: 10.1038/bmt.2015.351
Xiao Y, Song J, Jiang Z, Li Y, Gao Y, Xu W, et al. Risk-factor analysis of poor graft function after allogeneic hematopoietic stem cell transplantation. Int J Med Sci. 2014;11:652–7.
pubmed: 24834012
pmcid: 4021098
doi: 10.7150/ijms.6337
Sun YQ, He GL, Chang YJ, Xu LP, Zhang XH, Han W, et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol. 2015;94:1699–705.
pubmed: 26152553
doi: 10.1007/s00277-015-2440-x
Zhao Y, Gao F, Shi J, Luo Y, Tan Y, Lai X, et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2019;25:1898–907.
doi: 10.1016/j.bbmt.2019.05.036
Reich-Slotky R, Al-Mulla N, Hafez R, Segovia-Gomez J, Goel R, Mayer S, et al. Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2020;61:2894–9.
Prabahran A, Koldej R, Chee L, Wong E, Ritchie D. Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation. Leuk Lymphoma. 2021;62:1482–9.
Kako S, Yamazaki H, Ohashi K, Ozawa Y, Ota S, Kanda Y, et al. Mixed chimerism and secondary graft failure in allogeneic hematopoietic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transpl. 2020;26:445–50.
doi: 10.1016/j.bbmt.2019.10.004
Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transpl. 2007;40:431–5.
doi: 10.1038/sj.bmt.1705760
Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transpl. 2010;16:1099–106.
doi: 10.1016/j.bbmt.2010.02.013
Kanda J, Horwitz ME, Long GD, Gasparetto C, Sullivan KM, Chute JP, et al. Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2012;47:700–5.
pubmed: 21804612
doi: 10.1038/bmt.2011.158
Fuji S, Nakamura F, Hatanaka K, Taniguchi S, Sato M, Mori S, et al. Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2012;18:1407–14.
doi: 10.1016/j.bbmt.2012.02.014
Onishi Y, Mori T, Kako S, Koh H, Uchida N, Kondo T, et al. Outcome of second transplantation using umbilical cord blood for graft failure after allogeneic hematopoietic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2017;23:2137–42.
pubmed: 28844947
doi: 10.1016/j.bbmt.2017.08.020
Singh H, Nikiforow S, Li S, Ballen KK, Spitzer TR, Soiffer R, et al. Outcomes and management strategies for graft failure after umbilical cord blood transplantation. Am J Hematol. 2014;89:1097–101.
pubmed: 25195500
doi: 10.1002/ajh.23845
Subburaj D, Li AM, Rozmus J, Schultz KR. Successful rescue transplant for children with primary graft failure using early intervention with a single day preparative regimen and related haploidentical donor. Bone Marrow Transplant. 2021;56:2031–3.
pubmed: 33927347
doi: 10.1038/s41409-021-01309-7
Kliman D, Bilmon I, Kwan J, Blyth E, Micklethwaite K, Panicker S, et al. Rescue haploidentical peripheral blood stem cell transplantation for engraftment failure: a single-centre case series. Intern Med J. 2018;48:988–91.
pubmed: 30133987
doi: 10.1111/imj.13979